Issue Archive
May 2012 | Volume 11 | Issue 5
Editorials
When and How to Use Biologics
This supplement to the Journal of Drugs in Dermatology help address various components of psoriasis and comorbidities, as well as hidradenitis suppurativa and biologic treatments. Dr. Kircik and Onuma...
Read More
Original Articles
A New Simple, Safe, and Easy Solution for Upper Lip Dermabrasion
Background: Upper lip wrinkling is a common complaint of patients seeking perioral rejuvenation. Lately, manual dermabrasion has become more popular due to its safety, minimal cost, and favorable res...
Read MoreTreatment of Actinic Keratoses With 5% Topical Imiquimod: A Multicenter Prospective Observational Study from 93 Austrian Office-based Dermatologists
Background: While randomized, controlled trials have generated information about the safety and efficacy of imiquimod 5% cream in the treatment of actinic keratosis, still very little is known about ...
Read MoreTrends in Primary Skin Cancer Prevention Among US Hispanics: A Systematic Review
Objective: To evaluate trends and identify deficiencies and disparities in primary skin cancer prevention efforts among Hispanics in the US.
Methods: PubMed/MEDLINE and SCOPUS were searched usin...
Read MoreIn Vitro PLK1 Inhibition by BI 2536 Decreases Proliferation and Induces Cell-Cycle Arrest in Melanoma Cells
Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal. Polo-like kinase 1 (PLK1) has been shown to be over-expressed in a va...
Read MoreEvaluation of the Chemopreventative Effects of ALA PDT in Patients With Multiple Actinic Keratoses and a History of Skin Cancer
Background: Actinic keratoses (AKs) are in situ epidermal tumors that may progress to invasive squamous cell carcinomas (SCCs). Aminolevulinic acid with photodynamic therapy (ALA PDT) is a field treat...
Read MoreDiclofenac Sodium 3% Gel for the Management of Actinic Keratosis: 10+ Years of Cumulative Evidence of Efficacy and Safety
Background: Diclofenac sodium 3% gel (Solaraze®) gained US approval for the treatment of actinic keratosis (AK) more than 10 years ago. Since the publication of the pivotal phase 3 studies, numero...
Read MoreSarcoidosis as an Adverse Effect of Tumor Necrosis Factor Inhibitors
Background: Tumor necrosis factor inhibitors are valuable tools for dermatologists. As their use increases, rare adverse events are more likely to be encountered.
Objective: We describe one pati...
Read MoreImproved Texture and Appearance of Human Facial Skin After Daily Topical Application of Barley Produced, Synthetic, Human-like Epidermal Growth Factor (EGF) Serum
A three month, open-label, single center study was conducted to determine whether a uniquely derived serum containing barley bioengineered, human-like epidermal growth factor protein could improve vi...
Read MoreWhere Does Rituximab Fit in the Treatment of Autoimmune Mucocutaneous Blistering Skin Disease?
We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent bullous pemphigoid with or without systemic steroids. A brief review of the literature substantiates the signi...
Read MoreLessons of Leprosy: The Emergence of TH17 Cytokines During Type II Reactions (ENL) Is Teaching Us About T-cell Plasticity
Background: Leprosy was the first disease classified according to the thymus derived T-cell in the 1960s and the first disease classified by the cytokine profile as intact interferon-γ(IFN-&gamm...
Read MoreA Comparison of Physicochemical Properties of a Selection of Modern Moisturizers: Hydrophilic Index and pH
Objective: To quantify and compare the physiochemical properties of various topical emollients and to correlate these findings with the products' potential to maintain the stratum corneum (SC) acid mi...
Read MoreBiophysical Evaluation of Fractional Laser Skin Resurfacing With an Er:YSGG Laser Device in Japanese Skin
Background: Ablative fractional laser skin resurfacing (FLSR) has recently been used for the amelioration of acne scars, and previous studies have shown clinical effectiveness. Despite its extensive ...
Read MoreFitzpatrick Skin Types and Clindamycin Phosphate 1.2%/Benzoyl Peroxide Gel: Efficacy and Tolerability of Treatment in Moderate to Severe Acne
Background: Acne in skin of color is an increasing problem, presenting unique challenges. Although combination therapy is now standard of care in acne, concerns exist with the increased potential irri...
Read More
Features
RESIDENT ROUNDS: PART I
Program Spotlight: Department of Dermatology,Oregon Health & Science UniversityResident Rounds is a section of the JDD dedicated to highlighting various dermatology departments with residency training programs. Resident Rounds includes three sections: (1) a program spotlight, h...
Read MoreJDD: Celebrating 10 Years of Publishing Excellence
Skin Cancer: Prevention and Latest Treatments
RESIDENT ROUNDS: PART II
Contact Allergens Relevant to Dermatitis in Special LocationsRESIDENT ROUNDS: PART III
Lymphoepithelioma-like Carcinoma in a Patient With Mycosis FungoidesNEWS, VIEWS, & REVIEWS
Home Laser Treatments: Acne, Aging, and Unwanted HairPIPELINE PREVIEWS
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreCLINICAL TRIAL REVIEW
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read More
Case Reports
Infliximab (Remicade) and Increased Incidence of Development of Basal Cell Carcinoma
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-α (TNF-α) i...
Read MoreTreatment of Mild to Moderate Facial Melasma With the Lumixyl Topical Brightening System
Background: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl TM ) was previously shown to competitively inhibi...
Read More
